Cost Offsets: Studies suggest GLP-1 medications can reduce healthcare costs for diabetes-related complications by 20%30% annually per member
This approval, combined with its previous indications for adults with type 2 diabetes to improve glycemic control and reduce the risk of major cardiovascular events in adults with known heart disease, establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most widely indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class
Sig Transduct Target Ther
Cell Metabolism , 20(5), 779786
Clinical trials show approximately 25 to 39% of weight lost on semaglutide comes from lean body mass, but much of that is liver volume reduction and body water, not skeletal muscle
So far, most of this data comes from animal studies or early-phase research, not large human trials